Agios Pharmaceuticals reported a significant increase in product revenue to $55.4 million for Q3 2026, compared to $12.9 million in Q3 2025. Despite the revenue growth, the company recorded a net loss of $65.0 million for the quarter and $264.9 million for the first nine months of 2026, driven by high research and development and SG&A expenses.
Agios Pharmaceuticals reported Q3 2026 financial results, highlighted by record quarterly net product revenue of $55.4 million, a four-fold increase year-over-year driven by the U.S. launch of AQVESME in thalassemia. The company ended the quarter with $907 million in cash and is preparing for a potential February 2027 FDA approval of mitapivat in sickle cell disease.
Term
Q3 2026
“The third quarter was a record for our product revenue, outperforming our entire 2025 total in just three months. This growth was driven by the U.S. commercial launch of AQVESME in thalassemia, where broadening demand is translating into a durable base of patients on therapy.”
Brian Goff, Chief Executive Officer
“This launch has built the commercial foundation for our largest indication opportunity with mitapivat – sickle cell disease. Our conviction in mitapivat for patients with sickle cell disease is grounded in the robust efficacy and safety data generated to date and we are launch-ready ahead of our PDUFA goal date of February 1, 2027.”